Established in 2012, BioMarin Pharmaceutical Australia Pty Ltd brings first- or best-in-class therapies for patients living with rare genetic diseases. Our culture revolves around the ethos that no disease should go untreated, and our people are driven to discover, develop, and commercialise medicines that give patients, their families, and their caregivers hope where there was little or none.
VOXZOGO® was listed on the Pharmaceutical Benefits Scheme (PBS) from 1 May 2023 for patients with achondroplasia whose growth plates are not closed. KUVAN® PBS listing was expanded from 1 April 2023 to include adult patients with phenylketonuria (PKU).
We have multiple sites in Australia involved in our global clinical trial programs, including for treatments for achondroplasia, severe haemophilia A, and hereditary angioedema (HAE).
Focus on Diversity
The BioMarin community reflects the progress we have made in fostering a diverse, equitable, and inclusive workforce. For employees to reach their full potential, we must support them in every way – from embracing their unique backgrounds and experiences, to applying fair and equitable compensation practices.
To support our comprehensive DEI effort, we are actively pursuing three special areas of focus from 2022 to 2025:
• Increase Female Representation Among Top Leaders – Among top leadership, our percentage of women continues to increase, with the number of women VPs and above rising in four of the past five years. We are actively working to extend this upward trajectory and accelerate the addition of more women to our executive ranks.
• Increase People of Colour Representation – We are taking active steps to ensure more People of Color in Australia are represented at higher leadership levels, recruit more entry-level non-White talent, and provide biomedical education opportunities for underrepresented youth.
• Increase Pay Equity to the Fullest Extent Globally – We are an industry leader in pay equity, championing fair and equitable compensation for our employees. We will increase pay equity even more across our company, utilising all available data to ensure equity in each global region to the fullest extent possible.
It is up to all of us to protect our planet. As global citizens, we strive to operate in a way that protects the environment and provides a safe and healthful workplace for personnel and the communities that we serve.
Rare opportunities. Personal impact
Our employees feel connected to their work at BioMarin because they believe in our purpose: the patient. The passion and dedication that our employees bring to work each day is a testament to the inspiration patients living with rare diseases provide, and our knowledge of the impact we can make. Our appetite for science drives us. Our team members motivate us. And our patients inspire us. Together we’re growing a company unlike any other, because our motivation is unlike any other. Explore career opportunities on BioMarin.com – https://careers.biomarin.com/.
Our focus on rare disease gives us the rare opportunity to truly impact lives.
Dr Kathryn Evans
Managing Director, BioMarin Pharmaceutical Australia Pty Ltd
Senior Area Director, Australia and New Zealand
Our journey of fighting rare diseases started in 1997, at a time when the treatment of rare disease was still rare. With a relentless commitment to helping patients battle rare genetic diseases, BioMarin is resolved to overcome the biggest scientific challenges and has made numerous breakthroughs in developing innovative therapies for rare disease patients to achieve the optimal outcomes.
Products included in Australian Register of Therapeutic Goods (ARTG):
BRINEURA® (cerliponase alfa) for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.
KUVAN® (sapropterin dihydrochloride) Tablets for Oral Use and Powder for Oral Solution for the treatment of hyperphenylalaninemia (HPA) by reducing blood phenylalanine levels in patients with phenylketonuria (PKU) or tetrahydrobiopterin (BH4) deficiency.
PALYNZIQ® (pegvaliase) for the treatment of patients with phenylketonuria (PKU) whose blood phenylalanine levels cannot be adequately controlled by other means such as by diet.
NAGLAZYME® (galsulfase (rch)) for the treatment of Mucopolysaccharidosis VI (MPS VI) storage disorder, a disease in which the enzyme level of Nacetylgalactosamine 4-sulfatase is absent or lower than normal.
VOXZOGO® (vosoritide) for the treatment of achondroplasia in patients 2 years of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.
Treatments for severe haemophilia A, phenylketonuria (PKU), and hereditary angioedema (HAE).
Parent company: BioMarin Pharmaceutical Inc
This information is intended for healthcare professionals only. Please login/sign up to continue.
You are about to be redirected to the “IQVIA OneKey” healthcare professional authentication portal. By logging in (or signing up) for a OneKey account, you will be provided with access to the BioMarin Australia Healthcare Professional website.
You’re about to leave the BioMarin Australia website
The information that you are about to be referred to may not comply with the Australian regulatory requirements or be applicable to Australian users. For particulars specifically relevant to the Australian environment contact BioMarin Pharmaceutical Australia Pty Ltd or refer to the appropriate Product Information document.